Jürgen Finke

Jürgen Finke

Auto-generated profile, based on publicly available information

Jürgen Finke

Department of Hematology/Oncology, Faculty of Medicine, University of Freiburg Medical Center, Freiburg, Germany

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2009 in The Lancet Oncology
Verified
Journal Article
Closed access
JFJürgen Finke
Jürgen Finke
WBWolfgang A Bethge
Wolfgang A Bethge
CSClaudia Schmoor
Claudia Schmoor
HOHellmut D Ottinger
Hellmut D Ottinger
MSMatthias Stelljes
Matthias Stelljes
GSGérard Socié
Gérard Socié

13 May 2022 in Leukemia
Verified
Journal Article
Closed access
PDF file
AFAndrés José María Ferreri
Andrés José María Ferreri
KCKate Cwynarski
Kate Cwynarski
EPElisa Pulczynski
Elisa Pulczynski
CFChristopher P. Fox
Christopher P. Fox
ESElisabeth Schorb
Elisabeth Schorb
GIGerald Illerhaus
Gerald Illerhaus

20 August 2009 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CKCharalampia Kyriakou
Charalampia Kyriakou
CCCarmen Canals
Carmen Canals
JFJürgen Finke
Jürgen Finke
GKGuido Kobbe
Guido Kobbe
JHJean-Luc Harousseau
Jean-Luc Harousseau
NSNorbert Schmitz
Norbert Schmitz
Purpose: To analyze the long-term outcome in terms of nonrelapse mortality (NRM), relapse rate (RR), progression-free survival (PFS), and overall survival (OS) in patients with angioimmunoblastic T-cell lymphoma (AITL) treated with allogeneic stem-cell transplantation (alloSCT). Patients and Methods: Forty-five patients with AITL who had undergone an alloSCT between January 1998 and December 2005 and were registered in the European Group for Blood and Marrow Transplantation database were analyzed. Median age was 48 years (range, 23 to 68 years), 34 patients had received ≥ two lines of chemotherapy before alloSCT, and 11 patients had experienced treatment failure with a prior autologous stem-cell transplantation. Twenty-five patients underwent a myeloablative alloSCT, and 20 underwent a reduced-intensity alloSCT. Donors were HLA-identical siblings in 26 patients. Twenty-seven patients were allografted in chemotherapy-sensitive disease, and 18 were allografted in refractory disease. Results: The cumulative incidence of NRM was 18%, 22%, and 25% at 3, 6, and 12 months, respectively. Patients with poor performance status had a significantly higher NRM (P = .01). RR was estimated as 16% and 20% at 2 and 3 years, respectively, and was lower in patients developing chronic graft-versus-host disease (cGVHD). PFS and OS rates were 62% and 53% and 66% and 64% at 1 and 3 years, respectively, and were significantly better in chemotherapy-sensitive patients. Conclusion: AlloSCT represents a valid therapeutic option for patients with AITL. Both the lower RR after transplantation as well as the decreased RR in patients developing cGVHD after the alloSCT suggests the existence of a clinically relevant graft-versus-lymphoma effect.

20 March 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JMJurik A. Mutter
Jurik A. Mutter
SAStefan K. Alig
Stefan K. Alig
MEMohammad S. Esfahani
Mohammad S. Esfahani
ELEliza Lauer
Eliza Lauer
JMJan Mitschke
Jan Mitschke
FSFlorian Scherer
Florian Scherer
PURPOSE: Clinical outcomes of patients with CNS lymphomas (CNSLs) are remarkably heterogeneous, yet identification of patients at high risk for treatment failure is challenging. Furthermore, CNSL diagnosis often remains unconfirmed because of contraindications for invasive stereotactic biopsies. Therefore, improved biomarkers are needed to better stratify patients into risk groups, predict treatment response, and noninvasively identify CNSL. PATIENTS AND METHODS: We explored the value of circulating tumor DNA (ctDNA) for early outcome prediction, measurable residual disease monitoring, and surgery-free CNSL identification by applying ultrasensitive targeted next-generation sequencing to a total of 306 tumor, plasma, and CSF specimens from 136 patients with brain cancers, including 92 patients with CNSL. RESULTS: Before therapy, ctDNA was detectable in 78% of plasma and 100% of CSF samples. Patients with positive ctDNA in pretreatment plasma had significantly shorter progression-free survival (PFS, P < .0001, log-rank test) and overall survival (OS, P = .0001, log-rank test). In multivariate analyses including established clinical and radiographic risk factors, pretreatment plasma ctDNA concentrations were independently prognostic of clinical outcomes (PFS HR, 1.4; 95% CI, 1.0 to 1.9; P = .03; OS HR, 1.6; 95% CI, 1.1 to 2.2; P = .006). Moreover, measurable residual disease detection by plasma ctDNA monitoring during treatment identified patients with particularly poor prognosis following curative-intent immunochemotherapy (PFS, P = .0002; OS, P = .004, log-rank test). Finally, we developed a proof-of-principle machine learning approach for biopsy-free CNSL identification from ctDNA, showing sensitivities of 59% (CSF) and 25% (plasma) with high positive predictive value. CONCLUSION: We demonstrate robust and ultrasensitive detection of ctDNA at various disease milestones in CNSL. Our findings highlight the role of ctDNA as a noninvasive biomarker and its potential value for personalized risk stratification and treatment guidance in patients with CNSL. [Media: see text]

26 October 2008 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
GIG. Illerhaus
G. Illerhaus
RMR. Marks
R. Marks
FMF. Müller
F. Müller
GIG. Ihorst
G. Ihorst
FFF. Feuerhake
F. Feuerhake
JFJ. Finke
J. Finke
Background: To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and CCNU. To reduce neurotoxicity, whole-brain irradiation was reserved for patients not responding to chemotherapy. Patients and methods: High-dose MTX was applied on days 1, 15, and 30, procarbazine on days 1–10, and CCNU on day 1. Study treatment comprised up to three 45-day cycles. There was no lower limit of Karnofsky performance status (KPS). Results: Thirty patients with PCNSL (n = 29) or primary ocular lymphoma (n = 1) were included (median age 70 years, range 57–79 years). The median initial KPS was 60% (range 30%–90%). Best documented response in 27 assessable patients were 12 of 27 (44.4%) complete remissions, 7 of 27 (25.9%) partial remissions, and 8 of 27 (29.6%) disease progressions. Two patients died of probable treatment-related causes. With a median follow-up of 78 months (range 34–105), the 5-year overall survival is 33%. Eight of 30 patients (26.7%) are currently alive and well, six without signs of leukoencephalopathy. Conclusion: The combination of high-dose MTX with procarbazine and CCNU is feasible and effective and results in a low rate of leukoencephalopathy. Comorbidity and toxicity remain of concern when treating PCNSL in elderly patients.

1 June 2017 in The Lancet Haematology
Verified
Journal Article
Closed access
JFJürgen Finke
Jürgen Finke
CSClaudia Schmoor
Claudia Schmoor
WBWolfgang Andreas Bethge
Wolfgang Andreas Bethge
HOHellmut Ottinger
Hellmut Ottinger
MSMatthias Stelljes
Matthias Stelljes
GSGerard Socie
Gerard Socie